Influenza, human

This early-stage trial tested a new self-amplifying mRNA vaccine (ARCT-2304) designed to protect against pandemic influenza. 212 healthy adults aged 18-80 received either two doses of the experimental vaccine or one dose of a licensed flu vaccine plus placebo. Researchers monitor…

This trial is testing whether a single vaccine can protect against both influenza and COVID-19. Healthy adults aged 18 and older will receive either a combined vaccine, separate flu and COVID shots, or a placebo. The study will monitor safety and immune response over about six mo…

This phase 2b trial tests several versions of an experimental flu vaccine that includes an adjuvant (MF59) to strengthen the immune response. The vaccine is made from cells, not eggs, and targets four flu strains. Around 1,000 adults aged 50 and older receive a single shot and ar…

Pfizer completed a study testing a new modified RNA (mRNA) flu vaccine in 1,202 healthy adults aged 18 and older. The goal was to see if the vaccine is safe and triggers a strong immune response. Participants received either the experimental mRNA vaccine or a licensed flu shot, a…

This study tested new mRNA-based seasonal flu vaccines in 776 healthy adults aged 18 and older. The goal was to see how safe the vaccines are and how well they boost the immune system. Researchers measured side effects and immune responses to find the best vaccine candidate.

This study tested a booster vaccine for H5N6 bird flu in about 260 adults. Some had previously received an H5N1 bird flu vaccine, while others had not. The goal was to see if the booster was safe and triggered a strong immune response. Participants received one or two doses of th…

Pfizer is testing a new type of flu vaccine called a self-amplifying RNA (saRNA) vaccine. This early study involves 440 healthy adults aged 18 to 49. Participants receive either the saRNA vaccine, a licensed flu shot, or a placebo. The main goal is to check safety and side effect…

This early-stage trial tested an experimental mRNA-based flu vaccine in 324 healthy younger (18-45) and older (60-80) adults. The main goal was to check safety and how well the vaccine triggers an immune response. Participants received one of several dose levels or a placebo, and…

This study tested a new mRNA-based flu vaccine from GSK in 845 healthy adults aged 18 to 85. The goal was to find the best dose and check how well it triggers the immune system and whether it is safe. Results will help decide if larger studies should move forward.

This study tested a new mRNA vaccine designed to protect against a potential pandemic of H5 bird flu. Nearly 1,000 healthy adults aged 18 to 85 received different doses to find the safest and most effective one. Researchers monitored side effects like pain, fever, and fatigue, an…

This early-stage trial tested a new type of flu vaccine called ARCT-2138, which uses self-amplifying mRNA technology to potentially provide stronger and longer-lasting protection. The study involved 139 healthy adults aged 18-49 and 65-85, who received either the experimental vac…

This Pfizer trial tested whether a single injection combining an updated COVID-19 vaccine and a flu vaccine is safe and triggers a strong immune response. The study involved 644 healthy adults aged 50 and older. Researchers measured side effects and antibody levels to see if the …

This completed Phase 3 trial tested a quadrivalent (four-strain) influenza vaccine from Instituto Butantan in over 1,300 healthy infants and children aged 6 to 35 months. The study compared the immune response and safety of two doses (0.25ml and 0.50ml) against standard trivalent…

This study investigates the safety and how the body processes intravenous (IV) zanamivir in hospitalized infants under 6 months old with complicated influenza. Currently, no antiviral is approved for this age group, leaving them vulnerable. The trial will measure drug levels in t…

This study tested a new rapid test (LumiraDx Influenza A/B + RSV Test) that uses a nasal swab to quickly detect flu A, flu B, and RSV. Over 500 people with cold or flu-like symptoms took part. The test was performed by healthcare workers at point-of-care sites and compared to sta…

This study tests several new mRNA-based flu vaccines in about 971 healthy adults aged 18 and older. The goal is to see how well they trigger an immune response and how safe they are compared to standard flu shots. Participants receive one dose of an experimental vaccine or a comp…

This large study tested whether an enhanced flu vaccine (Fluad) works better than standard flu shots in adults aged 65 and older. Over 38,000 participants received either Fluad or a regular vaccine. The goal was to see if Fluad prevents confirmed flu cases more effectively. Resul…

This trial tests whether a recombinant flu vaccine (made in insect cells) works better than the standard egg-based flu shot at preventing flu illness in adults aged 18 to 64. About 4,000 college students and frontline workers will receive either vaccine and be monitored during fl…

This study tested several types of flu vaccines in over 1,800 adults aged 65-82 in Hong Kong over four years. The goal was to see which vaccine or combination of vaccines provides the strongest and longest-lasting immune protection. Researchers measured antibody levels and immune…

This completed study in Hong Kong enrolled 977 adults aged 18-45 to understand how getting the flu vaccine year after year changes the body's immune response. Participants received either the Flublok vaccine or a saline placebo. Researchers measured antibody levels and looked for…